In recent times cardiovascular diseases (CVDs) are the leading cause of mortality universally, caused more or less 17.7 million casualties with 45% of all illnesses (except communicable ones) in 2015 as per World Health Organization (WHO). According to American National Center for Health Statistics, cardiac disorders are costliest. Moreover, health care expenditures related to cardiac disorders are anticipated to exceed than diabetes and Alzheimer's. Straining of reactive oxygen species with diminished neutralization & inflammation critically adds to atherosclerosis and also proceed to other cardiovascular diseases such as cardiac remodeling and myocardial infarction (MI). In the past few years, researchers revealed multiple drug targets from animal studies and evaluated them in the therapeutics of cardiac disorders, which offered exciting clues for novel therapeutic strategies. Although, only few newer agents approved clinically and actual approaches for treatment are lagging behind. Several novel drugs found effective for the treatment of hypertension, congestive heart failure, cardiac arrhythmia and angina pectoris. Detailed mechanism of action, basic and clinical pharmacology of all novel drugs has been discussed in this review.

中文翻译：

---

心血管疾病新治疗靶点的最新进展。

近年来，心血管疾病 (CVD) 已成为普遍死亡的主要原因，根据世界卫生组织 (WHO) 的数据，2015 年，心血管疾病 (CVD) 造成约 1770 万人死亡，占所有疾病（传染病除外）的 45%。根据美国国家健康统计中心的数据，心脏病的成本最高。此外，与心脏病相关的医疗保健支出预计将超过糖尿病和阿尔茨海默病。活性氧的紧张以及中和和炎症的减弱会严重加剧动脉粥样硬化，还会导致其他心血管疾病，如心脏重塑和心肌梗塞 (MI)。在过去的几年中，研究人员从动物研究中发现了多个药物靶点，并在心脏疾病的治疗中对其进行了评估，这为新的治疗策略提供了令人兴奋的线索。尽管如此，只有少数新药获得临床批准，实际治疗方法仍然落后。几种新药被发现可有效治疗高血压、充血性心力衰竭、心律失常和心绞痛。本综述讨论了所有新药的详细作用机制、基础和临床药理学。